Demographic and clinical characteristics of the study subjects. Data are median (IQR) unless otherwise indicated.
| Characteristics | Nonresponders | Responders | p* | Partial Responders | Complete Responders |
|---|---|---|---|---|---|
| Total, n (female %) | 16 (100) | 93 (100) | 67 (100) | 26 (100) | |
| Age, yrs | 23.5 (21.0–28.5) | 29.0 (24.0–36.0) | 0.06 | 28. 0 (22.0–35.0) | 32.5 (27.0–43.0) |
| Height, cm | 159 (151–165) | 160 (156–164) | 0.90 | 160 (156–164) | 160 (156–163) |
| Weight, kg | 58.5 (48.5–64.3) | 53.0 (49.0–59.0) | 0.42 | 54.0 (50.0–59.0) | 50.0 (46.0–59.0) |
| BMI, kg/m2 | 22.2 (19.8–24.4) | 20.8 (19.0–23.0) | 0.42 | 21.3 (19.7–23.1) | 19.7 (18.8–21.3) |
| SLE duration, yrs | 3.50 (1.68–6.28) | 2.40 (0.74–5.50) | 0.16 | 3.10 (0.69–6.39) | 1.86 (0.74–4.18) |
| Class of lupus nephritis, n (%) | 0.37 | ||||
| Class III | 0 (0.0) | 11 (11.8) | 6 (9.0) | 5 (19.2) | |
| Class IV | 9 (56.3) | 43 (46.2) | 33 (49.3) | 10 (38.5) | |
| Class V | 1 (6.3) | 5 (5.4) | 3 (4.5) | 2 (7.7) | |
| Class III + V | 1 (6.3) | 9 (9.7) | 5 (7.5) | 4 (15.4) | |
| Class IV + V | 1 (6.3) | 15 (16.1) | 12 (17.9) | 3 (11.5) | |
| Not biopsied | 4 (25.0) | 10 (10.8) | 8 (11.9) | 2 (7.7) | |
| Proteinuria, mg/day | 2483 (1976–7088) | 3364 (1750–6500) | 0.44 | 4290 (2180–7150) | 1932 (1386–2833) |
| Serum creatinine, mg/dl | 0.80 (0.60–1.15) | 0.80 (0.70–0.90) | 0.56 | 0.80 (0.70–0.90) | 0.80 (0.70–0.90) |
| Serum C3, mg/dl | 55.2 (44.5–77.5) | 59.8 (44.9–82.9) | 0.79 | 61.5 (44.0–84.8) | 57.5 (49.2–76.1) |
| Serum C4, mg/dl | 13.3 (9.7–27.0) | 11.7 (7.7–17.6) | 0.96 | 11.6 (7.3–16.7) | 12.3 (9.2–17.8) |
| Positive anti-dsDNA antibody, n (%) | 10 (66.7) | 52 (58.4) | 0.55 | 41 (64.1) | 11 (44.0) |
| Cyclophosphamide total dose, mg | 4200 (3000–5250) | 4440 (3125–4800) | 0.97 | 4480 (3125–4797) | 4225 (3172–4800) |
↵* P values for the difference between the nonresponder and responder groups were obtained using median tests or chi-square tests. IQR: interquartile range; BMI: body mass index; SLE: systemic lupus erythematosus; C3: complement factor 3; C4: complement factor 4.